Innoviva Return On Equity vs. Current Valuation

INVA Stock  USD 18.99  0.06  0.31%   
Based on the key profitability measurements obtained from Innoviva's financial statements, Innoviva is yielding more profit at this time then in previous quarter. It has a moderate probability of reporting better profitability numbers in January. Profitability indicators assess Innoviva's ability to earn profits and add value for shareholders.
 
Return On Equity  
First Reported
2010-12-31
Previous Quarter
0.26627257
Current Value
0.26
Quarterly Volatility
0.81135031
 
Credit Downgrade
 
Yuan Drop
 
Covid
The current year's Operating Cash Flow Sales Ratio is expected to grow to 0.48, whereas Price To Sales Ratio is forecasted to decline to 3.21. At present, Innoviva's Operating Income is projected to increase significantly based on the last few years of reporting. The current year's Net Income is expected to grow to about 188.7 M, whereas Net Income From Continuing Ops is forecasted to decline to about 47.4 M.
For Innoviva profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Innoviva to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Innoviva utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Innoviva's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Innoviva over time as well as its relative position and ranking within its peers.
  

Innoviva's Revenue Breakdown by Earning Segment

Check out Risk vs Return Analysis.
For information on how to trade Innoviva Stock refer to our How to Trade Innoviva Stock guide.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innoviva. If investors know Innoviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innoviva listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.98)
Earnings Share
0.8
Revenue Per Share
5.6
Quarterly Revenue Growth
0.331
Return On Assets
0.0937
The market value of Innoviva is measured differently than its book value, which is the value of Innoviva that is recorded on the company's balance sheet. Investors also form their own opinion of Innoviva's value that differs from its market value or its book value, called intrinsic value, which is Innoviva's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innoviva's market value can be influenced by many factors that don't directly affect Innoviva's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innoviva's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innoviva is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innoviva's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Innoviva Current Valuation vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Innoviva's current stock value. Our valuation model uses many indicators to compare Innoviva value to that of its competitors to determine the firm's financial worth.
Innoviva is rated third overall in return on equity category among its peers. It is rated below average in current valuation category among its peers reporting about  13,832,252,036  of Current Valuation per Return On Equity. At present, Innoviva's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Innoviva's earnings, one of the primary drivers of an investment's value.

Innoviva Current Valuation vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Innoviva

Return On Equity

 = 

Net Income

Total Equity

 = 
0.0997
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Innoviva

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
1.38 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Innoviva Current Valuation vs Competition

Innoviva is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 64.85 Billion. Innoviva holds roughly 1.38 Billion in current valuation claiming about 2.13% of equities under Health Care industry.

Innoviva Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Innoviva, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Innoviva will eventually generate negative long term returns. The profitability progress is the general direction of Innoviva's change in net profit over the period of time. It can combine multiple indicators of Innoviva, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income176.7 M185.5 M
Net Income179.7 M188.7 M
Income Tax Expense14.4 M19.4 M
Income Before Tax194.1 M203.8 M
Total Other Income Expense Net17.4 M18.3 M
Net Income From Continuing Ops49.9 M47.4 M
Non Operating Income Net Other100.5 M105.5 M
Net Income Applicable To Common Shares246 M258.3 M
Interest Income14.2 M7.5 M
Net Interest Income-3 M-3.2 M
Change To Netincome-36.6 M-34.7 M
Net Income Per Share 2.75  2.88 
Income Quality 0.78  0.82 
Net Income Per E B T 0.93  1.21 

Innoviva Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Innoviva. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Innoviva position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Innoviva's important profitability drivers and their relationship over time.

Use Innoviva in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Innoviva position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Innoviva will appreciate offsetting losses from the drop in the long position's value.

Innoviva Pair Trading

Innoviva Pair Trading Analysis

The ability to find closely correlated positions to Innoviva could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Innoviva when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Innoviva - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Innoviva to buy it.
The correlation of Innoviva is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Innoviva moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Innoviva moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Innoviva can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Innoviva position

In addition to having Innoviva in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Large Growth Funds Thematic Idea Now

Large Growth Funds
Large Growth Funds Theme
Funds or Etfs that invest in stocks of large-sized companies with above-average risk and growth rate. The Large Growth Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Growth Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Innoviva offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innoviva's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innoviva Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innoviva Stock:
Check out Risk vs Return Analysis.
For information on how to trade Innoviva Stock refer to our How to Trade Innoviva Stock guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
To fully project Innoviva's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Innoviva at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Innoviva's income statement, its balance sheet, and the statement of cash flows.
Potential Innoviva investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Innoviva investors may work on each financial statement separately, they are all related. The changes in Innoviva's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Innoviva's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.